KL and nasopharyngeal carcinoma: Thyroid immune-related adverse events occurred in 32/153 (20.9%), similarly between groups (20.7 vs 21.1%, P = 0.957), and were not significantly associated with either OS (HR 0.65, 95% CI: 0.38-1.11, P = 0.117) or PFS (HR 0.88, 95% CI: 0.54-1.44, P = 0.613) by time-varying Cox regression.<h4>Conclusion</h4>Elevated basal TSH levels are independently associated with improved survival in R/M NPC patients receiving KL-A167.